BeiGene Receives Positive CHMP Opinion for TEVIMBRA® as a First-Line Treatment for Extensive-Stage Small Cell Lung Cancer
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 31 2025
0mins
Source: Newsfilter
Positive Opinion for TEVIMBRA: The European Medicines Agency's CHMP has issued a positive opinion recommending the approval of TEVIMBRA (tislelizumab) in combination with chemotherapy as a first-line treatment for extensive-stage small cell lung cancer, based on significant overall survival benefits demonstrated in the RATIONALE-312 study.
Impact on Cancer Treatment: The results from the study indicate a median overall survival of 15.5 months for patients receiving TEVIMBRA plus chemotherapy compared to 13.5 months for those on placebo, highlighting the potential of this treatment to improve outcomes for patients with this aggressive form of lung cancer.
Analyst Views on ONC
Wall Street analysts forecast ONC stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ONC is 403.76 USD with a low forecast of 385.00 USD and a high forecast of 424.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
11 Analyst Rating
11 Buy
0 Hold
0 Sell
Strong Buy
Current: 338.810
Low
385.00
Averages
403.76
High
424.00
Current: 338.810
Low
385.00
Averages
403.76
High
424.00
About ONC
BeOne Medicines AG, formerly BeiGene, Ltd., is a global oncology company engaged in discovering and developing treatments for cancer patients worldwide. With a portfolio spanning hematology and solid tumors, the Company is engaged in the development of its diverse pipeline of novel therapeutics. Its products include Brukinsa, Tevimbra and Pamiparib. Brukinsa is an orally available, small-molecule inhibitor of Bruton’s tyrosine kinase (BTK). Tevimbra is a humanized immunoglobulin G4 (IgG4) anti-programmed cell death protein 1 (PD-1) monoclonal antibody with high affinity and binding specificity against PD-1. It is designed to minimize binding to Fc-gamma (Fcy) receptors on macrophages, helping the body’s immune cells detect and fight tumors. The Company’s product pipeline in development includes Sonrotoclax, Tarlatamab, Zanidatamab, Blinatumomab, BGB-26808, BGB-R046, BG-68501, BG-C9074, BGB-43395, Xaluritamig, and others.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
